Crinetics Pharmaceuticals CRNX Collaboration and license revenue — Total Revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Crinetics Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Crinetics Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Crinetics Pharmaceuticals's collaboration and license revenue — total revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Crinetics Pharmaceuticals's collaboration and license revenue — total revenue?
- Crinetics Pharmaceuticals (CRNX) reported collaboration and license revenue — total revenue of $428K in Q1 2026.
- How has Crinetics Pharmaceuticals's collaboration and license revenue — total revenue changed year-over-year?
- Crinetics Pharmaceuticals's collaboration and license revenue — total revenue increased by 18.6% year-over-year, from $361K to $428K.
- What does collaboration and license revenue — total revenue mean?
- This metric represents the total revenue recognized from strategic partnerships, research collaborations, and the licensing of intellectual property or drug candidates to third parties. It reflects the company's ability to monetize its research and development pipeline through non-dilutive funding and milestone payments. Fluctuations in this revenue stream typically indicate the timing of clinical development milestones or the execution of new business development agreements.